300 related articles for article (PubMed ID: 28125758)
1. Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
Lipska KJ; Krumholz HM
JAMA; 2017 Mar; 317(10):1017-1018. PubMed ID: 28125758
[No Abstract] [Full Text] [Related]
2. Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
Fitchett D
Can J Diabetes; 2015 Dec; 39 Suppl 5():S176-82. PubMed ID: 26654861
[No Abstract] [Full Text] [Related]
3. Diabetes specialists keep ACCORD data in perspective.
Traynor K
Am J Health Syst Pharm; 2008 Mar; 65(6):488, 490. PubMed ID: 18319488
[No Abstract] [Full Text] [Related]
4. [New studies, new strategies, new guidelines: so that diabetic patients will live longer].
Aumiller J
MMW Fortschr Med; 2005 Oct; 147(41):4-6. PubMed ID: 16270500
[No Abstract] [Full Text] [Related]
5. Case study 1: exploring the pharmacologic agents for treatment of type 2 diabetes.
Martin CL
Diabetes Educ; 2007; 33 Suppl 1():6S-13S. PubMed ID: 17272803
[No Abstract] [Full Text] [Related]
6. [Intensive glucose control in type 2 diabetes is beneficial].
Nilsson PM; Attvall S
Lakartidningen; 2009 Sep 2-8; 106(36):2198. PubMed ID: 19817174
[No Abstract] [Full Text] [Related]
7. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riddle MC; Rydén L; Xavier D; Atisso CM; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona-Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw J; Sheu WH; Temelkova-Kurktschiev T;
Diabetes Obes Metab; 2018 Jan; 20(1):42-49. PubMed ID: 28573765
[TBL] [Abstract][Full Text] [Related]
8. Type 2 diabetes and HbA1c targets.
Prescrire Int; 2008 Dec; 17(98):254. PubMed ID: 19425272
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
[TBL] [Abstract][Full Text] [Related]
10. Individualizing glycemic targets in type 2 diabetes mellitus.
Aron D; Conlin PR; Hobbs C; Vigersky RA; Pogach L
Ann Intern Med; 2011 Sep; 155(5):340-1. PubMed ID: 21893635
[No Abstract] [Full Text] [Related]
11. Glucose lowering and cardiovascular disease: what do we know and what should we do?
Cheng AY; Leiter LA
Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S25-31. PubMed ID: 20489417
[TBL] [Abstract][Full Text] [Related]
12. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions.
Roussel R; Steg PG; Mohammedi K; Marre M; Potier L
Diabetes Obes Metab; 2018 Feb; 20(2):238-244. PubMed ID: 28597588
[TBL] [Abstract][Full Text] [Related]
13. Importance of glycemic control.
Shahady EJ
J Fam Pract; 2011 Sep; 60(9 Suppl):S4-6. PubMed ID: 21912776
[No Abstract] [Full Text] [Related]
14. Safety of very tight glucose control in type 2 diabetes in question.
Idris I
Diabetes Obes Metab; 2008 May; 10(5):438. PubMed ID: 18431839
[No Abstract] [Full Text] [Related]
15. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
Paty BW
Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
[TBL] [Abstract][Full Text] [Related]
16. Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.
Mannucci E; Monami M; Ceriello A; Rotella CM
Nutr Metab Cardiovasc Dis; 2017 Apr; 27(4):375-377. PubMed ID: 28242233
[No Abstract] [Full Text] [Related]
17. Update on the Canadian Diabetes Association 2008 clinical practice guidelines.
Bhattacharyya OK; Estey EA; Cheng AY;
Can Fam Physician; 2009 Jan; 55(1):39-43. PubMed ID: 19155364
[No Abstract] [Full Text] [Related]
18. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis.
Giugliano D; Chiodini P; Maiorino MI; Bellastella G; Esposito K
J Endocrinol Invest; 2019 Oct; 42(10):1165-1169. PubMed ID: 30955180
[TBL] [Abstract][Full Text] [Related]
20. [Intensive therapy in type 2 diabetes. More damage than benefit?].
Einecke D
MMW Fortschr Med; 2008 Jun; 150(26-27):12-4. PubMed ID: 18681224
[No Abstract] [Full Text] [Related]
[Next] [New Search]
